Literature DB >> 24259111

Comparability of self-reported medication use and pharmacy claims data.

Sara Allin1, Ahmed M Bayoumi, Michael R Law, Audrey Laporte.   

Abstract

BACKGROUND: Many studies of medicine use rely on self-reports. Based on pharmacy claims data, this analysis tests whether such self-reports constitute a valid and reliable data source. DATA AND METHODS: Linked data from the Canadian Community Health Survey and the Ontario Drug Benefit Program were used to estimate the agreement, based on kappa statistics, between seniors' self-reported medication use and the claims data. Health, demographic and socio-economic factors associated with the likelihood of agreement were modeled with logistic regression.
RESULTS: The prevalence of antihypertensive medication use among Ontario residents aged 65 or older was about 40% in 2001, based on both self-report and pharmacy claims, and in 2005, it was 52% for self-report and 49% based on claims data. The prevalence of oral diabetes medication use was comparable between the two data sources. Overall agreement between self-reported and claims data was "good" to "very good" for oral diabetes medications (kappa = 0.79 in 2001; 0.87 in 2005), but "moderate" for antihypertensive medications (kappa = 0.46 in 2001; 0.55 in 2005). Agreement improved somewhat from 2001 to 2005, with implementation of a more targeted survey question.
INTERPRETATION: Self-reports appear to be an accurate data source for measuring medication use; however, for antihypertensive medications, self-reports by the oldest and sickest subpopulations should be used cautiously.

Entities:  

Keywords:  aged; antihypertensive agents; diabetes; drug prescriptions; drug utilization; health surveys

Mesh:

Year:  2013        PMID: 24259111

Source DB:  PubMed          Journal:  Health Rep        ISSN: 0840-6529            Impact factor:   4.796


  7 in total

1.  Comparison of Pharmacy Database Methods for Determining Prevalent Chronic Medication Use.

Authors:  Timothy S Anderson; Bocheng Jing; Charlie M Wray; Sarah Ngo; Edison Xu; Kathy Fung; Michael A Steinman
Journal:  Med Care       Date:  2019-10       Impact factor: 2.983

2.  A systematic review of methods for determining cross-sectional active medications using pharmacy databases.

Authors:  Timothy S Anderson; Edison Xu; Evans Whitaker; Michael A Steinman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-13       Impact factor: 2.890

3.  Associations between medication use and homocysteine levels in an older population, and potential mediation by vitamin B12 and folate: data from the B-PROOF Study.

Authors:  Annelies C Ham; Anke W Enneman; Suzanne C van Dijk; Sadaf Oliai Araghi; Karin M A Swart; Evelien Sohl; Janneke P van Wijngaarden; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Tischa J M van der Cammen; M Carola Zillikens; Robert de Jonge; Paul Lips; Lisette C P G M de Groot; Joyce B J van Meurs; André G Uitterlinden; Renger F Witkamp; Bruno H C Stricker; Nathalie van der Velde
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

4.  Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.

Authors:  Lisandro D Colantonio; Shia T Kent; Meredith L Kilgore; Elizabeth Delzell; Jeffrey R Curtis; George Howard; Monika M Safford; Paul Muntner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-29       Impact factor: 2.890

5.  Validation of self-reported medication use for hypertension, diabetes, and dyslipidemia among employees of large-sized companies in Japan.

Authors:  Kota Fukai; Tomohisa Nagata; Koji Mori; Makoto Ohtani; Kenji Fujimoto; Masako Nagata; Yoshihisa Fujino
Journal:  J Occup Health       Date:  2020-01       Impact factor: 2.708

6.  Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.

Authors:  Rikke Viggers; Zheer Al-Mashhadi; Jakob Starup-Linde; Peter Vestergaard
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-19       Impact factor: 5.555

7.  The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.

Authors:  Rikke Viggers; Zheer Al-Mashhadi; Jakob Starup-Linde; Peter Vestergaard
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.